Detalles de la búsqueda
1.
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.
Anticancer Drugs
; 28(7): 677-701, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28542036
2.
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Anticancer Drugs
; 26(5): 565-72, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25643050
3.
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
Anticancer Drugs
; 26(4): 448-55, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25643049
4.
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Anticancer Drugs
; 25(7): 832-40, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24637575
5.
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
Mol Pharm
; 10(11): 4055-62, 2013 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24044612
6.
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Anticancer Drugs
; 24(10): 1084-92, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23969513
7.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol
; 13(9): 869-78, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22884505
8.
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Br J Clin Pharmacol
; 74(5): 788-96, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22458643
9.
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Drug Metab Dispos
; 39(8): 1460-7, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21602311
10.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Invest New Drugs
; 29(3): 499-505, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20094773
11.
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Pediatr Blood Cancer
; 54(5): 694-702, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20209646
12.
Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy.
Clin Transl Sci
; 13(2): 410-418, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31729137
13.
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
Clin Breast Cancer
; 9(1): 16-22, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19299235
14.
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.
Cancer Chemother Pharmacol
; 83(2): 329-340, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30467591
15.
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
Cancer Chemother Pharmacol
; 62(5): 779-86, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18205003
16.
Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Cancer Chemother Pharmacol
; 61(4): 607-14, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17549476
17.
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Eur J Clin Pharmacol
; 64(1): 31-41, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18000659
18.
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Cancer Chemother Pharmacol
; 79(2): 353-361, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28074265
19.
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Clin Pharmacol Ther
; 80(2): 136-45, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16890575
20.
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
J Clin Pharmacol
; 46(3): 282-90, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16490804